Century Therapeutics, Inc. (IPSC) Stock Price & Analysis

Century Therapeutics, Inc. (IPSC) fell 2.76% to USD 2.11 as of July 25, 2026 at 03:04 UTC, according to Nexqual real-time market data.

IPSC last closed at USD 2.17; the session ranged USD 2.08–2.18 on volume of 657,603 shares. Market capitalization is $380.55M, with a 52-week range of USD 0.44–3.04 (NCM). Source: Nexqual, July 25, 2026 at 03:04 UTC.

Key Statistics (as of July 25, 2026 at 03:04 UTC)

Technical Analysis (IPSC)

Nexqual's technical model rates IPSC "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:04 UTC.

Analyst Ratings (IPSC)

Wall Street analysts rate IPSC "None" based on 4 analysts, with a mean price target of USD 4.75 (range USD 2–8), per Nexqual as of July 25, 2026 at 03:04 UTC.

Earnings (IPSC)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 03:04 UTC.

Financials & Fundamentals (IPSC)

Source: Nexqual, July 25, 2026 at 03:04 UTC.

Financial Health Score (IPSC)

Nexqual rates Century Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:04 UTC.

Ownership (IPSC)

Source: Nexqual, July 25, 2026 at 03:04 UTC.

Leadership (IPSC)

Century Therapeutics, Inc. is led by Brent Pfeiffenberger M.B.A., Pharm.D. (age 47), President, CEO & Chairman, per Nexqual as of July 25, 2026 at 03:04 UTC.

Major Backers & Investors (IPSC)

Notable institutional backers of Century Therapeutics, Inc. include RA Capital Management, L.P., TCG Crossover Management, LLC, Versant Venture Management, LLC, according to Nexqual as of July 25, 2026 at 03:04 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 03:04 UTC.

From Century Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• We have sought patent protection in the United States and other countries throughout the world related to each of our pipeline programs, including our CNTY-101 product candidate, as well as other iPSC-derived engineered CAR-expressing and beta-islet cells comprising certain transgene insertions and deletions, including our proprietary Allo-Evasion™ technology.
• Incorporating industry-leading iPSC differentiation know-how, CRISPR-mediated precision gene editing, sophisticated protein engineering, proprietary Allo-Evasion™ technology, and cutting-edge manufacturing, we seek to provide patients with improved treatment options.
• Our first investigational solid tumor CAR-T cell program is designed to target validated tumor antigens including Nectin-4 (present on several solid tumors including urothelial cancer, breast cancer and lung cancer) and others using our own proprietary developed CAR moieties.
• This portfolio covers compositions of programmed cellular immunotherapies, our proprietary Allo-Evasion™ technology and our platform for industrial scale iPSC engineering and differentiation.

Partnerships

• On September 22, 2023, we entered into a worldwide license agreement with FCDI, or the Autoimmune License, whereby FCDI will grant non-exclusive licenses to us for certain patent rights and know-how related to cell differentiation and reprogramming for the development and commercialization of iPSC-derived therapies for the treatment of inflammatory and autoimmune diseases.
• Inscripta In January 2019, we entered into a non-exclusive license agreement with Inscripta, Inc.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:04 UTC. This page is informational and not investment advice.